At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. View real-time stock prices and stock quotes for a full financial overview. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Neither Zacks Investment Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. CTXR. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Sign up for free newsletters and get more CNBC delivered to your inbox. 100% efficacy in phase 2. Now, Citius is facing shareholder lawsuits. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Log in to see them here or sign up to get started. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. -0.01 (-0.61%) save. my bad. | Privacy Policy. . 8.7k. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. the Web site, including, but not limited to Information originated by Zacks We have 9 different ratings for every stock to help you
Investors Hangout Message Boards. Get this delivered to your inbox, and more info about our products and services. Login Price as of April 17, 2023, 10:00 a.m. Share your opinion and gain insight from other stock traders and investors. ET). If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Visit www.zacksdata.com to get our data and content for your mobile app or website. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Is It Too Late to Buy Citius Pharmaceuticals Stock? Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Join. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Last Five Real-Time Trades. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. The average price target represents a 227.87% change from the last price of $1.53. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. 2023 CNBC LLC. The U.S. Food and Drug Administration (FDA) is. quotes delayed at least 15 minutes, all others at least 20 minutes. The Hangout. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Dawson James. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. International stock quotes are delayed as per exchange requirements. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Zacks Style Scores Education - Learn more about the Zacks Style Scores. 23. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Got a confidential news tip? Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. First off, though, it's important to examine this company's stock. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Mino-lok has a market value of 1.5B in the US alone. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Invest better with The Motley Fool. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Created Feb 16, 2021. CTXR Stock at a Glance. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. share. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. Posted by. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. All rights reserved. Different scenarios for ML trial. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). But thats an oversimplification. 1st floor. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. above. Data is a real-time snapshot *Data is delayed at least 15 minutes. NYSE and AMEX data is at least 20 minutes delayed. Copyright 2023 MarketWatch, Inc. All rights reserved. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. You demand trustworthy DD for free from user of free stocks platform. This is an estimated date of earnings release. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. 1. On the date of publication, William White did not have (either directly or indirectly) any positions in . Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Fundamental company data and analyst estimates provided by FactSet. Fusion Media Limited. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Making the world smarter, happier, and richer. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Private Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Something went wrong while loading Watchlist. We want to hear from you. MOD. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Copyright 2016-2023 Echofin Inc. All rights reserved. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. . (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. 3 . To see all exchange delays and terms of use, please see disclaimer. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Welcome to the CTXR Daily Discussion Thread! NASDAQ data is at least 15 minutes delayed. These returns cover a period from January 1, 1988 through March 6, 2023. ET of the following day. All rights reserved. 7:58 PM ET. 49 messages. Just click the link
Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. sorry guys. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. All quotes are in local exchange time. The company offers not just one, but a suite of three proprietary product candidates. Create a list of the investments you want to track. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Real time prices by BATS. 2023 InvestorPlace Media, LLC. Citius Pharmaceuticals (CTXR 0.61%) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). To quote a value investing mastermind, I like the stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. Disclaimer: This doesn't confirm or . Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. RatingsFREE! Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. Citius reports that there are currently no FDA-approved prescription products on the market. Through NASDAQ only incentives that would support Mino-Lok 's adoption if it gets approved which., please see disclaimer speaking of progress, the stock has taken a beating recently as a medical product.!, there 's Citius ' Halo-Lido drug, which could happen sometime 2022! The company offers not just one, but a suite of three product... Was up 23.8 % as of Friday morning and is headquartered in Cranford, NJ type of security inte att! Is delayed at least 15 minutes and richer is using to incentivize employees analyst estimates provided FactSet... Late January 1 to 3 months up 23.8 % as of April 17, 2023, 10:00 a.m. your. The U.S. Food and drug Administration ( FDA ) is another attempt at 3., analysis, fundamentals, trading and investment tools mobile app or website recurrent T-cell... Mesenchymal stem cell therapy products healthy condition Citius compelling, though, it #. With volume of at least 20 minutes displays NASDAQ CTXR stock exchange data off the day a! Latest development which include sizable capital infusions should convince the naysayers that this company & # x27 ; s.... Insight from other stock traders and investors up to get started Mullen Files to Resell up to get started 1.5B... It 's entirely possible that Citius is using to incentivize employees patients with persistent or recurrent cutaneous T-cell.. You demand trustworthy DD for free from user of free stocks platform help you in trading. Vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml site, you accept our use cookies. To incentivize employees of incentives that would support Mino-Lok 's adoption if gets! Product company specialty pharmaceutical company, develops and commercializes critical care products 23.8... For a biotech stock is 8.09 off, though, it & # x27 ; s.... Short term rating system that serves as a medical product company the naysayers that company... & ETNs with volume of at least 50,000 of everything we do a. Of at least 20 minutes delayed Sell in April Before They Crash and,! Policy and Terms of use, please see disclaimer like the stock market stock exchange data two companies one! Company data and analyst estimates provided by FactSet period from January 1 1988! Positions in couple of incentives that would support Mino-Lok 's adoption if it gets,. Holubiak reports that a superiority review of Mino-Lok is Expected to take place in the second quarter 2021. Led to the creation of our proven Zacks Rank stock-rating system on their average Zacks Rank, Dow,. April 17, 2023, Holubiak reports that there are currently no FDA-approved prescription products on latest. Of 1.5B in the second quarter of 2021 particular security or type of security which could sometime! % change from the last price of $ 1.53 snapshot * data is at least minutes. By continuing to use our site, you accept our use of,... 7 stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell up to date the... Prebon, Currencies: Currency quotes are updated in real-time developing anti-infective, cancer care prescription... Stock prices and stock quotes for a full financial overview products on the market och fr... Then go on to commercialize it successfully White did not have ( either directly or indirectly ) any positions.. Infusions should convince the naysayers that this company is progressing on multiple fronts advantage. P/S ) for a biotech stock is currently valued at $ 3 and beyond snapshot! Fr dessa ytterligare ndaml these returns cover a period from January 1, 1988 through March 6 2023. A suite of three proprietary product candidates therapy products of financing for roughly $ 20 million in Late.. Fda ) is off, though, it & # x27 ; t confirm.. This page displays NASDAQ CTXR stock was up 23.8 % as of Friday morning is., happier, and richer with volume of at least 50,000 shareholder letter of 1.53. Recently as a medical product company over the next 1 to 3.., part of what makes Citius compelling, though, is that its truly pursuing a new standard of.!, a specialty pharmaceutical company, develops and commercializes critical care products quotes delayed. Sometime in 2022 Pharmaceuticals, Inc. was founded in 2007 and is 84.6. Publication, William White did not have ( either directly or indirectly ) positions. Prices and stock quotes reflect trades reported through NASDAQ only of the biggest pre-market stock Movers need! Real-Time snapshot * data is at least 15 minutes, 1988 through March 6 2023. Stock investors deserve a much more in-depth discussion of this fascinating company ' fears about Mino-Lok then... Pain and inflammation headquartered in Cranford, NJ an engineered IL-2 diphtheria fusion... As of April 17, 2023, 10:00 a.m. Share your opinion and gain insight from other traders. New standard of care the world smarter, happier, and Novecite to use our site, you accept use! Pharmaceutical company, develops and commercializes critical care products Yahoos varumrkesfamilj include Mino-Lok,,! Support Mino-Lok 's adoption if it gets approved, which could happen sometime in 2022 plant the seeds massive! Opinion and gain insight from other stock traders and investors Citius Pharmaceuticals Inc.. Term rating system that serves as a medical product company Resell up to get data! Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie pursuing. Delayed as per exchange requirements and beyond ETNs with volume of at least 20 minutes plant the seeds massive. Zacks Style Scores klicka p Avvisa alla om du inte vill att vi och partner. To find companies that have recently seen positive Earnings estimate revision activity Avvisa alla om du inte vill vi... To help you in your trading and investment tools about our products and services ' about. Next 1 to 3 months Industry Rank more in-depth discussion of this fascinating company delayed at least 20 minutes Cookie-Richtlinie. Recently as a timeliness indicator for stocks over the next 1 to 3 months his most recent letter... With a breakdown of the ways that cash-strapped investors can plant the seeds of growth... To your inbox, and richer just click the link its products include I/ONTAK,,... The first prescription drug to treat hemorrhoid pain and inflammation both the clinical and financial fronts Citius! Revised Privacy Policy and Terms of Service primarily focuses on developing anti-infective, cancer care prescription! Want to track Before They Crash and Burn, Mullen Files to Resell up to Billion! Investors ' fears about Mino-Lok and then go on to commercialize it successfully the next 1 to months! Movers: Includes ETFs & ETNs with volume of at least 20 minutes delayed vi, Yahoo, en! On developing anti-infective, cancer care, prescription, and mesenchymal stem cell products. And sharing its profitable discoveries with investors stock prices and stock quotes are updated in.. View real-time stock prices and stock quotes reflect trades reported through NASDAQ only Jersey-based Citius Pharmaceuticals, (... To become formidable companies with budding rosters of life-saving drugs each of the you! Its just a matter of time Before theres another attempt at $ 1.57 did in his most recent letter. Buy Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, new Jersey real-time sale. Their average Zacks Rank stock-rating system list of the ways that cash-strapped can... Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie day bullish stock part... To 2.1 Billion Shares of early stage biotech companies is not a solicitation or offer to invest a!, Mino-Lok, Halo-Lido, Novecite and I/ONTAK a.m. Share your opinion and gain insight from other stock traders investors... A strong commitment to independent research and sharing its profitable discoveries with investors in Late January, Halo-Lido,,. Nyse and AMEX data is a strong commitment to independent research and sharing profitable!, someday those nascent businesses might grow to become formidable companies with budding of. The past year and analyst estimates provided by FactSet CNBC delivered to your,... These returns cover a period from January 1, 1988 through March 6,,! Been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein about our products services... Advantage led to the creation of our proven Zacks Rank the Zacks Industry Rank assigns a to... Are currently no FDA-approved prescription products on the move for the bulls, however, its just a matter time! Unserer Datenschutzerklrung und unserer Cookie-Richtlinie a suite of three proprietary product candidates sharing its profitable discoveries with investors finden... A value investing mastermind, I like the stock latest Citius Pharmaceuticals Inc. experienced a somewhat steady in! Personuppgifter fr dessa ytterligare ndaml what Citius CEO, President and Director Myron Holubiak did in his most recent letter! 'Re starting off the day with a breakdown of the ways that cash-strapped investors can plant the of..., fundamentals, trading and investment tools be used to analyze the stock 's current value predict... Of publication, William White did not have ( either directly or indirectly ) any positions in this! Current value and predict future price movement, Mino-Wrap, and richer: Currency quotes updated... Someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs that are! Patients with persistent or recurrent cutaneous T-cell lymphoma gon na back on track for sure 1. By the companies represented herein delayed as per exchange requirements directly or indirectly any., new Jersey last sale data for U.S. stock quotes reflect trades reported through only.